These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 24976291)
1. Effect of fingolimod (FTY720) on cerebral blood flow, platelet function and macular thickness in healthy volunteers. Ocwieja M; Meiser K; David OJ; Valencia J; Wagner F; Schreiber SJ; Pleyer U; Ziemer S; Schmouder R Br J Clin Pharmacol; 2014 Dec; 78(6):1354-65. PubMed ID: 24976291 [TBL] [Abstract][Full Text] [Related]
2. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis. Singer B; Ross AP; Tobias K Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286 [TBL] [Abstract][Full Text] [Related]
3. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways. Zollinger M; Gschwind HP; Jin Y; Sayer C; Zécri F; Hartmann S Drug Metab Dispos; 2011 Feb; 39(2):199-207. PubMed ID: 21045200 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276 [TBL] [Abstract][Full Text] [Related]
5. Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Schmouder R; Hariry S; David OJ Eur J Clin Pharmacol; 2012 Apr; 68(4):355-62. PubMed ID: 22071882 [TBL] [Abstract][Full Text] [Related]
6. Fingolimod treatment in multiple sclerosis leads to increased macular volume. Nolan R; Gelfand JM; Green AJ Neurology; 2013 Jan; 80(2):139-44. PubMed ID: 23223539 [TBL] [Abstract][Full Text] [Related]
7. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. Kovarik JM; Lu M; Riviere GJ; Barbet I; Maton S; Goldwater DR; Schmouder RL Eur J Clin Pharmacol; 2008 May; 64(5):457-63. PubMed ID: 18196225 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effect of fingolimod (FTY720) on macular perfusion by swept-source optical coherence tomography angiography in patients with multiple sclerosis. Karaküçük Y; Gümüş H; Eker S Cutan Ocul Toxicol; 2020 Sep; 39(3):281-286. PubMed ID: 32657164 [TBL] [Abstract][Full Text] [Related]
10. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P; N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952 [TBL] [Abstract][Full Text] [Related]
11. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. Scott LJ CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study. Boulton C; Meiser K; David OJ; Schmouder R J Clin Pharmacol; 2012 Dec; 52(12):1879-90. PubMed ID: 22174429 [TBL] [Abstract][Full Text] [Related]
13. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis. Winges KM; Werner JS; Harvey DJ; Cello KE; Durbin MK; Balcer LJ; Calabresi PA; Keltner JL J Neuroophthalmol; 2013 Dec; 33(4):322-9. PubMed ID: 24051419 [TBL] [Abstract][Full Text] [Related]
14. Fingolimod for relapsing multiple sclerosis: an update. Horga A; Castilló J; Montalban X Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536 [TBL] [Abstract][Full Text] [Related]
15. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis. Vasiliou S Drugs Today (Barc); 2010 May; 46(5):315-25. PubMed ID: 20517533 [TBL] [Abstract][Full Text] [Related]